All news

23 October 2026

Investors sold, but cancer doctors call Moderna and Merck's melanoma vaccine a big step

Six melanoma specialists told CNBC the phase 3 vaccine results are a meaningful advance, even after Moderna stock fell as much as 25% when the data leaked.

Wall Street and the doctors who treat skin cancer came away from the same data with very different moods. Moderna shares fell as much as 25% on Thursday after partial results from its cancer vaccine trial with Merck leaked online. But six melanoma specialists told CNBC the results are a real advance that could become a standard treatment.

What happened

The vaccine, intismeran autogene, is built from each patient's own tumor mutations and teaches the immune system to hunt down any cancer cells left after surgery. In a trial of about 1,100 patients whose melanoma had been surgically removed, adding it to Merck's immunotherapy Keytruda cut the risk of the cancer returning or the patient dying by 42% versus Keytruda alone. The risk of the cancer spreading to distant organs, or death, fell by 38%.

That matters because melanoma that comes back and spreads to the lungs, brain or liver is much harder to treat. Doctors said stopping it from returning could spare patients that fight entirely. Moderna's CEO, Stéphane Bancel, called it "a very, very happy moment for the field, for patients." The company is finishing a filing with regulators and hopes for full approval next year.

Why investors were let down

Expectations were sky high. Moderna stock is up nearly 600% this year on hopes for the shot. An earlier phase 2 trial had shown about a 49% cut in risk at five years, and an RBC analyst wrote that the new headline figure landed at the low end of what investors hoped for, while still calling it clinically meaningful.

One investigator noted the bigger trial included lower-risk patients, who have less chance of relapse to begin with, which may have pulled the number down. The benefit also seemed to build over time: the two treatments looked similar for the first six months, but after that point the combination cut risk by 58%. Each shot takes about six weeks to make, and the immune system needs repeated doses to respond, though doctors said that explanation is still a hypothesis.

Even after Thursday's drop, Moderna was valued at about $81 billion at the October 22 close, against a net loss of about $3.2 billion in its latest reported figures, according to filings via Noorult. Merck was worth about $364 billion.

What to watch

  • Full results and safety data at the European Society for Medical Oncology meeting on Saturday.
  • Whether the shot helps patients live longer, which is not yet known.
  • Cost and scale: each vaccine is custom-made, and the companies have not disclosed manufacturing costs.

Company pages on Noorult: Moderna and Merck.

The companies in this story

Based on reporting by CNBC: Moderna, Merck's cancer vaccine data a major advancement. Facts, not advice.

More news